News

Interview with Joel S. Freundlich



Dr. Joel S. Freundlich
Dr. Joel S. Freundlich



Dr. Joel S. Freundlich attended Cornell University as a McMullen scholar and an Exxon scholar, attaining his B.S. degree with Distinction in Chemical Engineering in 1991 and his M. Eng. degree in Chemical Engineering in 1992. He received his Ph.D. degree in 1996 in Organic Chemistry with Richard R. Schrock – the 2005 Nobel Prize in Chemistry recipient. Dr. Freundlich was an active researcher in the biotech industry for ten years. His achievements are highlighted by contributions to three clinical submissions.

He is currently a Senior Research Scientist in the Biochemistry and Biophysics department at Texas A&M University and a Visiting Professor at Rutgers University in the Medicinal Chemistry department. His research seeks to leverage chemical techniques to 1) understand critical biological processes within Mtb that are essential to its lifecycle and interactions with the human immune system and 2) leverage this knowledge of essential enzyme and/or pathways to seed the discovery of novel antitubercular drugs.

This interview was conducted at JHU on November 13, 2009.

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...